Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse pipeline of drug candidates, underpinned by rigorous research methodologies and clinical trials that validate their efficacy and safety profiles. With a leadership team experienced in biopharmaceuticals and strong strategic partnerships, Zura Bio is well-positioned to capitalize on growth opportunities in the sector, making it an attractive investment prospect for institutional investors seeking exposure to innovative therapeutic solutions.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$6.23
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 11, 2026 | $-0.20 | $-0.21 | Miss -5.0% | $-0.21 | $0 | $0 | — | 1D Pre-5.6% | On-Day-1.2% | 1D Post+4.0% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-0.18 | $-0.22 | Miss -22.2% | — | $0 | $0 | — | 1D Pre-5.6% | On-Day-7.2% | 1D Post+5.5% |
Q ended Dec 31, 2025 Reported Mar 19, 2026 | $-0.15 | $-0.49 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-7.0% |
| On-Day+2.2% |
| 1D Post-10.1% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-0.18 | $-0.21 | Miss -16.7% | — | $0 | $0 | — | 1D Pre+4.8% | On-Day-9.7% | 1D Post-2.4% |